These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 26082654)
1. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review. Rocchi A; Chabot I; Glennie J Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654 [TBL] [Abstract][Full Text] [Related]
2. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups. Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233 [TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. Raymakers AJN; Regier DA; Peacock SJ Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234 [TBL] [Abstract][Full Text] [Related]
4. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations. Binder L; Ghadban M; Sit C; Barnard K Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327 [TBL] [Abstract][Full Text] [Related]
5. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia. Ball G; Levine MAH; Thabane L; Tarride JE Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879 [TBL] [Abstract][Full Text] [Related]
6. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans. Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C Front Pharmacol; 2019; 10():196. PubMed ID: 30983993 [TBL] [Abstract][Full Text] [Related]
7. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. McDonald H; Charles C; Elit L; Gafni A J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586 [TBL] [Abstract][Full Text] [Related]
8. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications. Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. Meyers DE; Jenei K; Chisamore TM; Gyawali B JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606 [TBL] [Abstract][Full Text] [Related]
10. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study. Lexchin J BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254 [TBL] [Abstract][Full Text] [Related]
11. The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison. Skedgel C Curr Oncol; 2016 Oct; 23(5):322-328. PubMed ID: 27803596 [TBL] [Abstract][Full Text] [Related]
12. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review. Niraula S Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671 [TBL] [Abstract][Full Text] [Related]
13. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding. Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796 [TBL] [Abstract][Full Text] [Related]
14. Impact of rarity on Canadian oncology health technology assessment and funding. Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560 [TBL] [Abstract][Full Text] [Related]
15. Determinants of the Cancer Drug Funding Process in Canada. Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362 [TBL] [Abstract][Full Text] [Related]
16. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada. Rawson NSB; Stewart DJ Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711 [TBL] [Abstract][Full Text] [Related]
17. Examining the association between oncology drug clinical benefit and the time to public reimbursement. Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587 [TBL] [Abstract][Full Text] [Related]
18. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs. Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460 [TBL] [Abstract][Full Text] [Related]
19. Conditional approval of cancer drugs in Canada: accountability and impact on public funding. Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815 [TBL] [Abstract][Full Text] [Related]
20. An institutional ethnographic analysis of public and patient engagement activities at a national health technology assessment agency. Bidonde J; Vanstone M; Schwartz L; Abelson J Int J Technol Assess Health Care; 2021 Feb; 37():e37. PubMed ID: 33557969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]